Delfi Diagnostics Announces $225 Million Series B Financing To Develop Globally Accessible Portfolio Of Liquid Biopsy Tests

Jul 18, 2022•over 3 years ago

Amount Raised

$225 Million

Round Type

series b

Palo AltoBiotechnology

Description

Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, today announced a Series B funding of $225 million.

Company Information

Company

DELFI Diagnostics

Location

1810 Embarcadero Road

Palo Alto, California, United States

About

DELFI Diagnostics is developing next-generation blood-based cancer detection tests designed to be accurate, accessible, and scalable for population health. Its technology is based on fragmentomics, using machine learning to analyze patterns in cell-free DNA from a simple blood draw. DELFI’s first test, FirstLook Lung, supports lung cancer screening by reliably identifying individuals who may have cancer, including early-stage disease, with a 99.8% negative predictive value.

Related People

6 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech